| 注册
首页|期刊导航|临床与病理杂志|埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效

埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效

黄章洲 林贤东 许春伟 陈刚 陈燕坪 庄武 黄韵坚 朱有才 杜开齐 方美玉 王晓江 师怡

临床与病理杂志2017,Vol.37Issue(3):500-504,5.
临床与病理杂志2017,Vol.37Issue(3):500-504,5.DOI:10.3978/j.issn.2095-6959.2017.03.009

埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效

Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21 rare mutations

黄章洲 1林贤东 2许春伟 2陈刚 2陈燕坪 2庄武 1黄韵坚 1朱有才 3杜开齐 3方美玉 4王晓江 2师怡2

作者信息

  • 1. 福建医科大学附属福建省肿瘤医院胸部肿瘤内科,福州 350014
  • 2. 福建医科大学附属福建省肿瘤医院病理科,福州 350014
  • 3. 浙江省荣军医院胸部疾病中心,浙江 嘉兴 314000
  • 4. 浙江省肿瘤医院综合肿瘤内科,杭州 310022
  • 折叠

摘要

Abstract

Objective: To investigate the efficacy of icotinib in patients with non-small cell lung cancer (NSCLC) that carrying L861Q/L833F in EGFR exon 21. Methods: We retrospectively analysed 17 cases of EGFR 21 exon rare mutation NSCLC patients until the progress of the disease or the emergence of the side effects, and clinical efficacy was observed after months followed-up. Results: Seventeen patients with L861Q/L833F mutations were enrolled. Mutations including L861Q and L833F mutations were observed in 17 and 1 patients, respectively. In total, the median progression-free survival (PFS) were 2.2 months, respectively. Patients with L833F mutation manifested the longest median PFS (4.2 months), followed by those with L861Q (2.2 months). Patients with complex mutations show a better PFS than those with single mutations (L861Q mutations 2.1 months vs. 5.6 months, P=0.065). Conclusion: Icotinib is less effective in patients with exon 21 uncommon mutations than in those with common mutations. Patients with complex mutations benefited more from icotinib than those with single mutations.

关键词

非小细胞肺癌/埃克替尼/21外显子

Key words

non-small-cell lung cancer/icotinib/exon 21

引用本文复制引用

黄章洲,林贤东,许春伟,陈刚,陈燕坪,庄武,黄韵坚,朱有才,杜开齐,方美玉,王晓江,师怡..埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效[J].临床与病理杂志,2017,37(3):500-504,5.

基金项目

国家临床重点专科建设项目(2013) (2013)

福建省科技厅引导性项目(2016Y0019) (2016Y0019)

福建省科技厅引导性项目(2015Y0011) (2015Y0011)

浙江省卫生科研计划基金 (2013KYB051) (2013KYB051)

浙江省中医药局科研基金 (2013ZQ005) (2013ZQ005)

浙江省科技厅公益类科研计划 (2015C33194).This work was supported by National Clinical Key Specialty Construction Program (2013) (2015C33194)

Leading Project Foundation of Science Department of Fujian Province (2016Y0019) (2016Y0019)

Leading Project Foundation of Science Department of Fujian Province (2015Y0011) (2015Y0011)

Medical Scientific Research Foundation of Zhejiang Province of China (2013KYB051) (2013KYB051)

Zhejiang Administration of Traditional Chinese Medicine Foundation (2013ZQ005) (2013ZQ005)

the Science and Technology Planning Project of Zhejiang Province of China (2015C33194). (2015C33194)

临床与病理杂志

OACSTPCD

1673-2588

访问量0
|
下载量0
段落导航相关论文